# NCT03794544 (NCT03794544)

> Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03794544
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: MedImmune LLC
- Conditions: Resectable; Early-stage; NSCLC
- Interventions: Durvalumab; Oleclumab; Monalizumab; Danvatirsen
- Enrollment: 84
- Primary outcome: Major Pathological Response Rate

## Commentary we found

- X threads: 9
- YouTube: 7
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct03794544

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03794544", "email": "<work email>"}; the inbox owner confirms by the emailed link.